Patents by Inventor Ernest Hamel

Ernest Hamel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthesis for the preparation of compounds for screening as potential tubulin binding agents
    Publication number: 20050130221
    Abstract: The present invention relates to methods for the synthesis of chemical compounds for screening as potential tubulin polymerization inhibitors. The invention also provides chemical compounds with tubulin polymerization inhibitor activity.
    Type: Application
    Filed: February 1, 2002
    Publication date: June 16, 2005
    Applicants: The Australian National University, The Government of the United States as Represented by The Secretary of the Dept. of Health and Human
    Inventors: Bernard Flynn, Ernest Hamel
  • B-homoestra-1,3,5(10)-trienes as modulators of tubulin polymerization
    Patent number: 6696436
    Abstract: The invention provides B-ring expanded estra-1,3,5(10)-triene compounds of general formula (1) which modulate the polymerization of tubulin and/or the depolymerization of microtubules. The compounds have anti-angiogenic and anti-tumor activity. The invention also provides methods of preparing the compounds, and methods of using the compounds for the treatment of cancer or other mammalian diseases characterized by undesirable angiogenesis. The compounds of the invention are also expected to have utility as research tools.
    Type: Grant
    Filed: August 16, 2002
    Date of Patent: February 24, 2004
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ernest Hamel, Mark S. Cushman
  • Stilbene derivatives as anticancer agents
    Patent number: 5430062
    Abstract: The present invention relates to stilbene derivatives which possess utility as anti-cancer agents. The compounds can be used to treat cancers which are susceptible to treatment therewith, and can be utilized in a method of treating such cancers. Pharmaceutical compositions containing the compounds are disclosed. Three preferred compounds among those disclosed are (Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene, (Z)-1-(4-methylphenyl)-2-(3,4,5-trimethoxyphenyl)ethene, and 4-methyl-3',4',5'-trimethoxybenzylaniline hydrochloride.
    Type: Grant
    Filed: June 23, 1993
    Date of Patent: July 4, 1995
    Assignee: Research Corporation Technologies, Inc.
    Inventors: Mark S. Cushman, Ernest Hamel